[Therapies for intractable respiratory infection due to Pseudomonas aeruginosa].
Nasu
Masaru
M
D018829:Adhesins, Bacterial; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology; D001422:Bacterial Adhesion; D001428:Bacterial Vaccines / Q000627:therapeutic use; D018441:Biofilms / Q000187:drug effects; D001988:Bronchiolitis / Q000382:microbiology* / Q000503:physiopathology / Q000628:therapy*; D002908:Chronic Disease; D003428:Cross Infection / Q000382:microbiology* / Q000628:therapy*; D015964:Gene Expression Regulation, Bacterial / Q000187:drug effects / Q000235:genetics; D006801:Humans; D037102:Lectins / Q000037:antagonists & inhibitors; D018942:Macrolides / Q000008:administration & dosage / Q000494:pharmacology; D018410:Pneumonia, Bacterial / Q000382:microbiology* / Q000503:physiopathology / Q000628:therapy*; D011379:Prognosis; D011552:Pseudomonas Infections; D011550:Pseudomonas aeruginosa / Q000472:pathogenicity*; D020545:Respiratory Mucosa / Q000382:microbiology; D015398:Signal Transduction / Q000235:genetics
D018829:Adhesins, Bacterial; D000900:Anti-Bacterial Agents; D001428:Bacterial Vaccines; D037102:Lectins; D018942:Macrolides; C038692:adhesin, Pseudomonas